UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Link zum Volltext

Verfügbarkeit prüfen

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

The Lancet (British edition), 2019-05, Vol.393 (10184), p.1948-1957

2019

Link zum Volltext

Verfügbarkeit prüfen

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Journal of clinical oncology, 2019-05, Vol.37 (15), p.1277-1284

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

Journal of clinical oncology, 2017-01, Vol.35 (2), p.226-235

2017

Link zum Volltext

Verfügbarkeit prüfen

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Clinical cancer research, 2021-02, Vol.27 (4), p.1003-1011

2021

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-01, Vol.20 (1), p.43-56

2019

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

The lancet oncology, 2020-12, Vol.21 (12), p.1574-1588

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

The Lancet (British edition), 2019-01, Vol.393 (10167), p.156-167

2019

Link zum Volltext

Verfügbarkeit prüfen

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Journal of clinical oncology, 2019-04, Vol.37 (12), p.984-991

2019

Link zum Volltext

Verfügbarkeit prüfen

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2017-11, Vol.35 (31), p.3529-3537

2017

Link zum Volltext

Verfügbarkeit prüfen

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

The Lancet (British edition), 2017-03, Vol.389 (10073), p.1011-1024

2017

Link zum Volltext

Verfügbarkeit prüfen

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Blood, 2017-11, Vol.130 (22), p.2392-2400

2017

Link zum Volltext

Verfügbarkeit prüfen

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

The Lancet (British edition), 2020-11, Vol.396 (10262), p.1563-1573

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Journal of clinical oncology, 2019-05, Vol.37 (13), p.1062-1069

2019

Link zum Volltext

Verfügbarkeit prüfen

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Journal of clinical oncology, 2018-08, Vol.36 (23), p.2395-2404

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2017-06, Vol.317 (23), p.2392

2017

Link zum Volltext

Verfügbarkeit prüfen

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

The New England journal of medicine, 2018-03, Vol.378 (13), p.1177-1188

2018

Link zum Volltext

Verfügbarkeit prüfen

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

The lancet oncology, 2020-11, Vol.21 (11), p.1433-1442

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 86.205

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77.048)
Mit Volltextzugriff
(63.170)

Publikationsform

Sprache

Englisch
(74.512)
Japanisch
(14.552)
Chinesisch
(1.223)
Deutsch
(1.213)
Französisch
(1.129)
Russisch
(820)
Spanisch
(516)
Polnisch
(302)
Italienisch
(294)
Ungarisch
(142)
Portugiesisch
(70)
Tschechisch
(67)
Niederländisch
(56)
Bulgarisch
(31)
Hebräisch
(31)
Norwegisch
(31)
Dänisch
(25)
Ukrainisch
(24)
Rumänisch
(17)
Serbian
(17)

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(84.325)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(65.678)
Science & Technology
(64.184)
Life Sciences & Biomedicine
(63.628)
Female
(58.924)
Male
(48.955)
Middle Aged
(48.870)
Oncology
(47.348)
Aged
(40.989)
Adult
(39.325)
Biological And Medical Sciences
(26.489)
Medical Sciences
(26.443)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(24.106)
Antineoplastic Combined Chemotherapy Protocols - Administration & Dosage
(23.011)
Treatment Outcome
(22.740)
Chemotherapy
(21.685)
Cisplatin - Administration & Dosage
(19.867)
Fluorouracil - Administration & Dosage
(15.692)
Pharmacology. Drug Treatments
(15.347)
Combined Modality Therapy
(14.512)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ingenta.com
(39.920)
EZB Electronic Journals Library
(36.224)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(35.328)
IngentaConnect Journals
(22.361)
NUS Single-Journal Subscriptions
(20.131)
Elsevier ScienceDirect Journals Complete
(13.777)
SpringerLink
(11.049)
Wiley Online Library
(10.233)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(8.861)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(8.719)
Wiley Online Library
(8.267)
Taylor & Francis Current Content Access
(3.717)
Springer Nature - Connect here FIRST to enable access
(3.522)
Taylor & Francis Journals Complete
(3.477)
SpringerLink Series
(2.738)
Nexis
(2.455)
Oxford University Press Journals Current
(1.845)
Oxford Journals 2020 Medicine
(1.570)
Sage Journals Online
(1.289)
BMJ
(728)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Gan To Kagaku Ryoho
(4.871)
Journal Of Clinical Oncology
(4.725)
Cancer
(2.543)
Annals Of Oncology
(2.450)
Cancer Chemotherapy And Pharmacology
(1.917)
Anticancer Research
(1.617)
British Journal Of Cancer
(1.509)
Gynecologic Oncology
(1.426)
Clinical Cancer Research
(1.288)
European Journal Of Cancer
(1.287)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Pembrolizumab for Early Triple-Negative Breast Cancer

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety

Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Suchergebnisse filtern